Journal Information
Vol. 10. Issue 2.
Pages 145-154 (March - April 2004)
Share
Share
Download PDF
More article options
Vol. 10. Issue 2.
Pages 145-154 (March - April 2004)
ARTIGO DE REVISÃO/REVISION ARTICLE
Open Access
Aspectos pulmonares na deficiência de alfa-1-antitripsina
Pulmonary aspects in alpha-1-antitrypsin deficiency
Visits
6533
Luiza Érika Schmid Melo Neto, Cyro Teixeira da Silva Junior, Gilberto Perez Cardoso, Ângela Santos Ferreira, Guilherme da Costa Marino, Nicolau Pedro Monteiro
Trabalho realizado pelo Programa de Pós-Graduação Stricto Sensu em Ciências Médicas, Universidade Federal Fluminense, Niterói, Estado do Rio de Janeiro, Brasil
This item has received

Under a Creative Commons license
Article information
RESUMO

A deficiência de α-1-antitripsina é uma desordem genética de herança autossómica recessiva, tendo como fenótipo mais comum o inibidor de protease tipo ZZ. A doença predomina em indivíduos brancos de origem europeia, e a sua frequência, tanto na Europa, como na América do Norte, é comparável à da fibrose quística (1:2000 a 1:7000). Os indivíduos com esta deficiência podem ser assintomáticos, sendo que a manifestação mais prevalente, também apontada como a maior causa de invalidez e morte nesses pacientes, é a doença pulmonar obstrutiva crónica. Nos indivíduos portadores da doença, o tabagismo constitui o factor de risco mais importante. A doença é muito pouco diagnosticada. Várias estratégias de tratamento têm sido utilizadas.

REV PORT PNEUMOL 2004; X (2): 145-154

Palavras-chave:
alfa-1-antitripsina
doença pulmonar obstrutiva crónica
ABSTRACT

Alpha-1-antitrypsin deficiency is an autosomal hereditary disorder and the large majority of individuals with severe deficiency are protease inhibitor type ZZ. The disease occurs predominantly in white persons of European origin and its frequency in Europe and North America is comparable to that of cystic fibrosis (1 in 2000 to 1 in 7000). Persons with this deficiency may have no clinical manifestations, but the most prevalent clinical disorder associated, also pointed as the most frequent cause of disability and death, is chronic obstructive pulmonary disease. In those individuals, tobacco smoking is the major risk. The condition appears to be widely underdiagnosed, based on studies. Several strategies have been explored in the treatment of this deficiency.

REV PORT PNEUMOL 2004; X (2): 145-154

Key-words:
alpha-1-antitripysin
chronic obstructive pulmonary disease
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
R.F. Behrsin.
Cirurgia redutora de volume pulmonar: critérios de seleção de pacientes no Hospital Universitário Antônio Pedro (dissertação de mestrado).
Universidade Federal Fluminense, (1999),
[2.]
R.W. Carrell, D.A. Lomas.
Alpha1-Antitrypsin Deficiency – A Model for Conformational Diseases.
New England Journal of Medicine, 346 (2002), pp. 45-53
[3.]
R.J. Coakley, C. Taggart, S. O’Neill, N.G. Mcelvaney.
α-1-Antitrypsin Deficiency: Biological Answers to Clinical Questions.
The American Journal of the Medical Sciences, 321 (2001), pp. 33-41
[4.]
Consenso Brasileiro De Doença Pulmonar Obstrutiva Crônica.
J Pneumol, 26 (2000), pp. S1-S56
[5.]
L.C. Corrêa Da Silva.
Doença Pulmonar Obstrutiva Crônica.
Condutas em Pneumologia, 1a ed, pp. 637-654
[6.]
A. Cuvelier, J.F. Muir, M.F. Hellot, D. Benhamou, J.P. Martin, J. Benichou, R. Sesboue.
Distribution of α-1-Antitrypsin Alleles in Patients with Bronchiectasis.
Chest, 117 (2000), pp. 415-419
[7.]
M. Dahl, A. Tybjaerg-Hansen, P. Lange, J. Vestbo, B.G. Nordestgaard.
Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in α-1-Antitrypsin MZ Heterozygotes: A Longitudinal Study of General Population.
Annals of Internal Medicine, 136 (2002), pp. 270-279
[8.]
M. Dahl, G. Borge, B.G. Nordestgaard, P. Lange, J. Vestbo, Tybjaerg-Hansen.
Molecular Diagnosis of Intermediate and Severe α-1-Antitrypsin Defi ciency: MZ Individuals with Chronic Obstructive Pulmonary Disease May Have Lower Lung Function than MM Individuals.
Clinical Chemistry, 47 (2001), pp. 56-62
[9.]
L.J. Dowson, P.J. Guest, S.L. Hill, R.A. Stockley.
High-resolution computed tomografy scanning in α-1-an-titrypsin deficiency: relationship to lung function and health status.
Eur Respir J, 17 (2001), pp. 1097-1104
[10.]
E. Eden, D. Mitchell, B. Mehlman, H. Khouli, M. Nejat, M.H. Grieco, G.M. Turino.
Atopy, Asthma, and Emphysema in Pacients with Severe α-1-Antitrypsin Deficiency.
American Journal of Respiratory Critical Care, 156 (1997), pp. 68-74
[11.]
T.J. Layden, L. Kulik.
Hepatic manifestations of pulmonary diseases.
Clin Liver Dis, 6 (2002), pp. 969-979
[12.]
F.C. Luft.
Alpha1-antitrypsin and its relevance to human disease.
J Mol Med, 77 (1999), pp. 359-360
[13.]
R. Mahadeva, D.A. Lomas.
Genetics and respiratory disease 2. Alpha1-antitrypsin deficiency, cirrhosis and emphysema.
Thorax, 53 (1998), pp. 501-505
[14.]
Lung Function and Death from Chronic Obstructive Pulmonary Disease in α-1-Antitrypsin MZ Heterozygotes.
Annals of Internal Medicine, (2002), pp. 135
[15.]
E. Pitulainen, G. Tornling, S. Eriksson.
Environmental correlares of impaired lung function in non-smokers with severe α-1-antitrypsin deficiency (PiZZ).
Thorax, 53 (1998), pp. 939-943
[16.]
R.A. Primhak, M.S. Tanner.
Alpha-1 antitrypsin deficiency.
Arch Dis Child, 85 (2001), pp. 2-5
[17.]
R.A. Sandhaus.
Alpha-1-Antitrypsin Deficiency Therapy: Pieces of the Puzzle.
Chest, 119 (2001 Mar), pp. 676-678
[18.]
R.A. Stockley.
Alpha-1-antitrypsin deficiency: what next?.
Thorax, 55 (2000), pp. 614-618
[19.]
J. West, D.M. Rodman.
Gene Therapy for Pulmonary Diseases.
Chest, 119 (2001), pp. 613-617
[20.]
World Health Organization.
α-1-Antitrypsin deficiency: Memorandum from a WHO meeting.
Bulletin of the World Health Organization, 75 (1997), pp. 397-415
Copyright © 2004. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?